CR20120449A - Formas de rifaximina y sus usos - Google Patents

Formas de rifaximina y sus usos

Info

Publication number
CR20120449A
CR20120449A CR20120449A CR20120449A CR20120449A CR 20120449 A CR20120449 A CR 20120449A CR 20120449 A CR20120449 A CR 20120449A CR 20120449 A CR20120449 A CR 20120449A CR 20120449 A CR20120449 A CR 20120449A
Authority
CR
Costa Rica
Prior art keywords
forms
rifaximine
rifaximin
relates
present
Prior art date
Application number
CR20120449A
Other languages
English (en)
Inventor
Karen S Gushurst
Donglai Yang
Petinka Vlahova
Jeffrey S Stults
Original Assignee
Salix Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salix Pharmaceuticals Ltd filed Critical Salix Pharmaceuticals Ltd
Publication of CR20120449A publication Critical patent/CR20120449A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a formas polimórficas de Rifaximina, a su uso en preparaciones medicinales y a métodos terapéuticos que las utilizan.
CR20120449A 2010-02-19 2012-08-29 Formas de rifaximina y sus usos CR20120449A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12/708,836 US8486956B2 (en) 2008-02-25 2010-02-19 Forms of rifaximin and uses thereof

Publications (1)

Publication Number Publication Date
CR20120449A true CR20120449A (es) 2012-11-29

Family

ID=44483273

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20120449A CR20120449A (es) 2010-02-19 2012-08-29 Formas de rifaximina y sus usos

Country Status (21)

Country Link
US (5) US8486956B2 (es)
EP (1) EP2536734B1 (es)
JP (2) JP2013520427A (es)
KR (1) KR20120140244A (es)
CN (2) CN105254647A (es)
AU (3) AU2011218258B2 (es)
BR (1) BR112012020863A2 (es)
CA (1) CA2790332A1 (es)
CR (1) CR20120449A (es)
EA (1) EA201270722A1 (es)
GE (2) GEP20156230B (es)
IL (1) IL221299A (es)
MA (1) MA34058B1 (es)
MX (1) MX353827B (es)
MY (1) MY158992A (es)
NZ (1) NZ601670A (es)
PH (1) PH12012501623A1 (es)
SG (1) SG183188A1 (es)
TN (1) TN2012000414A1 (es)
WO (1) WO2011103120A1 (es)
ZA (1) ZA201206227B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3001996A (en) * 1957-02-08 1961-09-26 Hans S Mannheimer Sulfates and sulfonates of n-tertiary amino alkyl-carboxylic acid amides
PT1698630E (pt) 2005-03-03 2014-09-15 Alfa Wassermann Spa Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
US8486956B2 (en) 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
US8067429B2 (en) 2008-02-25 2011-11-29 Salix Pharmaceuticals, Ltd. Forms of rifaximin and uses thereof
BRPI0920465A2 (pt) 2008-10-02 2018-03-20 Salix Pharmaceuticals, Inc. metodo de tratamento de encefalopatia hepática
US7928115B2 (en) 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
US12285414B2 (en) 2008-10-02 2025-04-29 Salix Pharmaceuticals, Inc. Methods of treating hepatic encephalopathy
WO2011061748A1 (en) * 2009-11-19 2011-05-26 Strides Arcolab Limited Rifaximin premix
US9018684B2 (en) 2009-11-23 2015-04-28 California Institute Of Technology Chemical sensing and/or measuring devices and methods
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
WO2011153444A1 (en) * 2010-06-03 2011-12-08 Salix Pharmaceuticals, Ltd New forms of rifaximin and uses thereof
CA2802874A1 (en) * 2010-06-16 2011-12-22 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
SMT202000390T1 (it) * 2010-07-12 2020-09-10 Salix Pharmaceuticals Inc Formulazioni di rifaximina e loro usi
CN103221032A (zh) * 2010-09-13 2013-07-24 西普拉有限公司 药物组合物
WO2012109605A2 (en) 2011-02-11 2012-08-16 Salix Pharmaceuticals, Ltd. Forms of rifaximin and uses thereof
CA2834829A1 (en) * 2011-05-02 2012-11-08 Ranbaxy Laboratories Limited Rifaximin dimethylformamide solvate
ITMI20110890A1 (it) * 2011-05-19 2012-11-20 A M S A Anonima Materie Sint & Affini S P A Polimorfo di rifaximina e processo per la sua preparazione
US20130184302A1 (en) 2011-11-02 2013-07-18 Enoch Bortey Methods for treating irritable bowel syndrome (ibs) and infections
JP2013184902A (ja) * 2012-03-06 2013-09-19 Aska Pharmaceutical Co Ltd リファキシミン含有結晶
US9359374B2 (en) 2012-06-13 2016-06-07 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
CN105324109A (zh) 2013-04-12 2016-02-10 意大利阿尔法韦士曼制药公司 Nsaid施用和相关的组合物、方法和系统
CN103509038B (zh) * 2013-09-30 2016-01-20 浙江思贤制药有限公司 一种新晶型利福昔明ζ及其制备方法
EP2927235B1 (en) 2014-03-31 2017-02-08 Euticals S.P.A. Polymorphic mixture of rifaximin and its use for the preparation of solid formulations
CA2947962C (en) 2014-05-04 2024-01-16 Salix Pharmaceuticals, Inc. Ibs microbiota and uses thereof
AU2015260837B2 (en) 2014-05-12 2019-02-28 Alfasigma S.P.A. New solvated crystal form of rifaximin, production, compositions and uses thereof
WO2016204474A2 (ko) * 2015-06-18 2016-12-22 주식회사대성미생물연구소 리팍시민 결정체를 포함하는 동물 장염 치료용 수의학적 조성물
CA3038312A1 (en) 2016-09-30 2018-04-05 Salix Pharmaceuticals, Inc. Solid dispersion forms of rifaximin
CA3184054A1 (en) 2020-06-26 2021-12-30 Jacob Cole Targeted release rifaximin compositions
CN117447487A (zh) * 2022-07-19 2024-01-26 重庆圣华曦药业股份有限公司 一种利福昔明的纯化方法及其在利福昔明片剂中的应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1154655B (it) 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
IT1199374B (it) * 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
IL150524A0 (en) 2000-01-07 2003-02-12 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US7906542B2 (en) * 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
US7923553B2 (en) * 2003-11-07 2011-04-12 Alfa Wassermann, S.P.A. Processes for the production of polymorphic forms of rifaximin
US20080262024A1 (en) 2003-11-07 2008-10-23 Giuseppe Claudio Viscomi Rifaximin compositions and method of use
US7902206B2 (en) * 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
DE102004004433A1 (de) 2004-01-28 2005-08-18 Trützschler GmbH & Co KG Vorrichtung an einer Spinnereimaschine, insbesondere Karde, Reiniger o. dgl., zum Aufziehen einer Garnitur auf eine Walze
CA2574307A1 (en) * 2004-07-22 2006-02-02 Cumbre Pharmaceuticals Inc. Rifamycin derivatives for treating microbial infections
US8003118B2 (en) * 2005-03-02 2011-08-23 Kodsi Robert E Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis
PT1698630E (pt) * 2005-03-03 2014-09-15 Alfa Wassermann Spa Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
EP2069363B1 (en) * 2006-09-22 2013-03-20 Cipla Ltd. Rifaximin in an amorphous form
US20100136125A1 (en) 2006-12-28 2010-06-03 Jacobus Pharmaceutical Company, Inc. Method of treating inflammatory bowel disease
ITMI20071241A1 (it) 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
JP5755878B2 (ja) * 2007-07-06 2015-07-29 ルパン リミテッドＬｕｐｉｎ Ｌｉｍｉｔｅｄ リファキシミンの薬剤組成物
MY144578A (en) * 2007-07-27 2011-10-14 Alfa Wassermann Spa New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
US7709634B2 (en) * 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
WO2009047801A1 (en) 2007-10-10 2009-04-16 Lupin Limited Therapeutic combinations and compositions for the treatment of gastrointestinal disorders
US8067429B2 (en) 2008-02-25 2011-11-29 Salix Pharmaceuticals, Ltd. Forms of rifaximin and uses thereof
US8486956B2 (en) 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
HRP20140939T1 (hr) * 2008-05-07 2014-11-21 Salix Pharmaceuticals, Ltd. Davanje preparata za äśišä†enje crijeva i antibiotika za lijeäśenje bolesti crijeva
AU2009292615B2 (en) 2008-09-17 2015-12-03 Mylan Inc. Granulates, process for preparing them and pharmaceutical products containing them
US8916193B2 (en) 2008-12-10 2014-12-23 Cipla Limited Rifaximin complexes
RU2012121599A (ru) 2009-10-27 2013-12-10 Люпин Лимитед Твердая дисперсия рифаксимина
US8952159B2 (en) 2009-12-28 2015-02-10 Silvio Massimo Lavagna Method for the production of amorphous rifaximin
WO2011153444A1 (en) * 2010-06-03 2011-12-08 Salix Pharmaceuticals, Ltd New forms of rifaximin and uses thereof
CA2802874A1 (en) * 2010-06-16 2011-12-22 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
WO2012109605A2 (en) * 2011-02-11 2012-08-16 Salix Pharmaceuticals, Ltd. Forms of rifaximin and uses thereof

Also Published As

Publication number Publication date
AU2014246594A1 (en) 2014-10-30
CN102834398A (zh) 2012-12-19
US8486956B2 (en) 2013-07-16
MX2012009576A (es) 2012-12-05
JP2016094416A (ja) 2016-05-26
AU2016269529B2 (en) 2018-06-07
US9273066B2 (en) 2016-03-01
MA34058B1 (fr) 2013-03-05
SG183188A1 (en) 2012-09-27
US20140179916A1 (en) 2014-06-26
HK1179608A1 (zh) 2013-10-04
EP2536734B1 (en) 2016-08-31
CA2790332A1 (en) 2011-08-25
US20100174064A1 (en) 2010-07-08
KR20120140244A (ko) 2012-12-28
US20140141081A1 (en) 2014-05-22
NZ601670A (en) 2014-11-28
EP2536734A1 (en) 2012-12-26
AU2011218258A1 (en) 2012-08-30
GEP20156230B (en) 2015-01-26
IL221299A0 (en) 2012-10-31
EP2536734A4 (en) 2013-06-26
US20120316334A1 (en) 2012-12-13
PH12012501623A1 (en) 2012-10-22
EA201270722A1 (ru) 2013-03-29
AU2016269529A1 (en) 2017-01-05
US9034892B2 (en) 2015-05-19
US20160200738A1 (en) 2016-07-14
JP2013520427A (ja) 2013-06-06
WO2011103120A1 (en) 2011-08-25
BR112012020863A2 (pt) 2016-06-21
US8569326B2 (en) 2013-10-29
AU2014246594B2 (en) 2016-09-15
IL221299A (en) 2017-11-30
MX353827B (es) 2018-01-31
US9546183B2 (en) 2017-01-17
ZA201206227B (en) 2018-12-19
MY158992A (en) 2016-11-30
AU2011218258B2 (en) 2015-11-05
TN2012000414A1 (en) 2014-01-30
CN105254647A (zh) 2016-01-20
GEP201706745B (en) 2017-10-10

Similar Documents

Publication Publication Date Title
MX353827B (es) Formas de rifaximina y usos de la misma.
CR20130033A (es) Formulaciones de rifaximina y usos de las mismas
CR20150401A (es) Formas de rifaximina y sus usos
UY34876A (es) Anticuerpos anti-egfr y usos de los mismos
UY34680A (es) Anticuerpos humanos anti-cd27, métodos, y usos
MX2012013945A (es) Nuevas formas de rifaximina y usos de las mismas.
MX2015003140A (es) Formulaciones de enzalutamida.
UY34484A (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
MX2017007585A (es) Anticuerpos anti-c10orf54 y usos de los mismos.
UY34350A (es) Derivados de pirazolquinolinona, su preparación y su uso terapéutico.
UY34764A (es) Derivados de 2,2-difluoropropionamida de metilo de bardoxolona, formas polimórficas y sus métodos de uso
DOP2015000219A (es) Compuestos de heteroarilo y sus usos
UY34271A (es) Anticuerpos anti-tie2 y usos de los mismos
CL2015002567A1 (es) Compuestos y sus usos para modular la hemoglobina
UY34721A (es) Anticuerpos anti-hla-b*27 y usos de éstos.
GT201400127A (es) Anticuerpos anti-phf-tau y sus usos
CL2015003801A1 (es) Formulaciones de anticuerpos y metodos
MX2015011514A (es) Compuestos de heteroarilo y sus usos.
AR089993A1 (es) Macrociclos peptidomimeticos
ECSP15043696A (es) Compuestos de heteroarilo y sus usos
GT201400147A (es) Pirimidinas y triazinas fusionadas sustituidas y su uso
MX379193B (es) Composiciones en solucion solida y su uso en inflamacion cronica.
CL2016001509A1 (es) Formas cristalinas de los análogos de sofosbuvir antivirales
CR20130458A (es) Formas sólidas sde 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona, y sus composiciones farmacéuticas y usos
UY34278A (es) Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades